**Star News, Dongcheng Pharmaceutical (002675) replied to investors' concerns on the investor relations platform on February 28.
Investors:Dear Secretary of the Board of Directors: Hello, please reply to the inquiry information sent to your company's mailbox.
Secretary of the Board of Directors of Dongcheng Pharmaceutical:Hello, the previous email has been replied, please check the email in time! Thank you for your interest!
Investors:Dear Secretary of the Board of Directors: Hello, please reply to the inquiry of shareholder information sent to your company's mailbox, thank you.
Secretary of the Board of Directors of Dongcheng Pharmaceutical:Hello, the previous email has been replied, please check the email in time! Thank you for your interest!
Investors:Dear Secretary of the Board of Directors, the inquiry letter sent to the company's mailbox has not been replied for a long time, please confirm the reply in a timely manner, I am grateful.
Secretary of the Board of Directors of Dongcheng Pharmaceutical:Hello, the previous email has been replied, please check the email in time! Thank you for your interest!
Investors:Dear Mr. Chairman and Secretary of the Board of Directors, why did you not reply to the inquiry information sent to your company's mailbox in the early stage? In this **unstable, continuous stock price**, for small and medium-sized investors, we should reply to the demands of small and medium-sized investors in a timely manner, increase the confidence of investors in the company's growth, and hope to give a confirmation reply in their busy schedules, which is grateful. At the same time, it is hoped that the company will make further breakthroughs in the nuclear drug product line, bring about the growth of performance, and repay the support of all shareholders.
Secretary of the Board of Directors of Dongcheng Pharmaceutical:Hello, the previous email has been replied, please check the email in time! Thank you for your interest!
Investors:Dear management of Dongcheng Pharmaceutical, your company's ESG rating shows that the overall ESG rating has hovered in B in recent years, but the rating in terms of governance is only BBB, as a company in the pharmaceutical and biological industry, how do you see the role of governance in ensuring product safety and quality management? In addition, in light of the improvement in your governance rating, do you have any plans to increase your ESG disclosures and publish more detailed sustainability reports?
Secretary of the Board of Directors of Dongcheng Pharmaceutical:Hello, thank you for your attention, thank you!
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.